CRNO B
6.07 SEK
-0.03 (-0.41%)

Capital Markets Day 2022

Cereno invites analysts, investors, and financial media to join us for insights into our strategy and operations.

The Capital Markets Day 2022 was held on Tuesday, August 30, 2022, at 14:30-17:30 at Helio GT30, Grev Turegatan 30, in Stockholm.

Access the video recording of the event

Download the presentation

Agenda

The event starts at 14:30 with coffee and networking, before the program starts at 15:00.

Time
Program

15:00

Welcome
Lars Frick
Moderator

15:05

Cereno’s Commitment to Transforming Cardiovascular Disease Management
Sten R. Sörensen
CEO, Cereno

15:20

Overview of Cardiovascular Disease and Cereno’s Focus Areas
Dr. Björn Dahlöf
CMO, Cereno

15:30

Understanding PAH: Debilitating Rare Disease
Dr. Raymond Benza
Prof. and Director at the Ohio State University Wexner Medical Center; PI of Phase II study with CS1

15:45

Clinical Phase II Study Design with CS1
Dr. Raymond Benza
Prof. and Director at the Ohio State University Wexner Medical Center; PI of Phase II study with CS1

15:50

CardioMEMS – Phase II Clinical Collaboration Between Abbott and Cereno
Dr. Phil Adamson
Divisional Vice President and Chief Medical Office Heart Failure Division, Abbott

16:05

Cereno’s Drug Candidate CS1 to Treat PAH and Broader Potential
Dr. Björn Dahlöf
CMO, Cereno

16:20

Cereno’s Preclinical Candidates Potential to Break New Ground
Dr. Björn Dahlöf
CMO, Cereno

16:25

CS585 – A First-In-Class Compound Targeting the IP Receptor for Prevention of Thrombosis Without Increased Risk of Bleeding
Dr. Michael Holinstat
Ass. Prof. at University of Michigan Medical School; and Director Translation Research, Cereno

16:40

CS014 – A Novel HDAC Inhibitor Regulating Platelet Activity, Fbrinolysis and Clot Stability for Prevention of Thrombosis Without Increased Risk of Bleeding
Dr. Michael Holinstat
Ass. Prof. at University of Michigan Medical School; and Director Translation Research, Cereno

16:55

Panel: The Need for True Innovation in CVD Management – Focus on PAH and Thrombosis

Moderated by moderator

Dr. Björn Dahlöf
Dr. Gunnar Olsson
Dr. Michael Holinstat
Dr. Phil Adamson

17:10

Questions from Audience
Moderated by moderator

17:20

Concluding Words
Sten R. Sörensen
CEO, Cereno